Skip to main content
MMedVellum
MCQsExamsAtlas
DashboardPricing
MMedVellum

The exam atlas that feels like a flagship product — evidence-graded topics and exam tools for MBBS and fellowship preparation. Built to scale to fifty specialties. Educational content only — not medical advice.

llms.txt·psychiatry LLM catalog · sitemap

Atlas

  • Specialty atlas
  • MBBS / Core medicine
  • Dermatology
  • ICU Fellowship (CICM)
  • Anaesthesia
  • Emergency Medicine
  • Psychiatry Fellowship

Study & account

  • MCQ practice
  • Practice alias
  • Exam tools
  • Dashboard
  • Pricing
  • Sign in

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

Clinical Atlas Prestige · Evidence-first

Psych MEQs / SAQsConsultation-liaison psychiatry

Psych MEQs / SAQs · Consultation-liaison psychiatry

SSD, illness anxiety, and chronic pain dual diagnosis (MEQ)

FRANZCP-style MEQ on SSD vs IAD, PHQ-15, CBT evidence, SNRI/TCA caution, and opioid dual-diagnosis principles.

20 marks20 min
On this page & tools

Target exams

FRANZCPMRCPsychABPNMD-DNB

Target exams

FRANZCPMRCPsychABPNMD-DNB
Prompt
A 47-year-old woman is referred to C-L after a third medical admission this year for chest tightness, abdominal pain, and fatigue. Extensive cardiac, GI, and endocrine work-ups are unrevealing. She scores high on PHQ-15, meets criteria for major depression, catastrophises about undiagnosed cancer, and has been started on oxycodone PRN by multiple GPs. She becomes angry when a junior doctor says 'it is all psychological.' (i) Formulate DSM-5-TR diagnoses and discriminators from IAD, FND, factitious disorder, and malingering. (ii) Outline assessment priorities including scales and opioid risk. (iii) Present a stepped management plan with psychological evidence and cautious medication options (named agents/doses). (iv) Address the opioid interface and communication strategy. (20 marks)

Model answer

Reveal model answer

(i) Formulation and discriminators. Working diagnoses: somatic symptom disorder (multiple distressing somatic symptoms with disproportionate health anxiety and care-seeking) plus major depressive disorder. SSD does not require symptoms to be medically unexplained; the B-criteria (thoughts/feelings/behaviours) are central.[1] Discriminators: IAD would show minimal somatic symptoms with pure illness preoccupation; FND needs voluntary motor/sensory symptoms with positive functional signs; factitious requires intentional production for sick role; malingering intentional production for external incentive — neither is default without evidence. Keep organic red-flag surveillance open despite prior negative work-ups.[1][7]

(ii) Assessment. Alliance-first history; PHQ-15 severity; depression/anxiety/suicide risk; substance and opioid map (dose trajectory, multiple prescribers, withdrawal, OUD criteria, concurrent sedatives); prior investigations and what would change management; function and health beliefs; collateral GP. Investigations hypothesis-driven only.[2][8]

(iii) Stepped plan. Validate symptoms as real; positive non-dualistic explanation; scheduled GP reviews rather than PRN crisis only; limit unfocused tests; CBT for health anxiety/MUS (Barsky; Tyrer CHAMP; Cochrane non-pharmacological signal).[3][4][7] Treat depression. Consider duloxetine (commonly 30 mg oral daily then 60 mg) if pain–depression phenotype and no contraindications, or cautious low-dose night amitriptyline 10–25 mg oral for pain with anticholinergic/cardiac cautions — evidence humility required.[6] Functional goals (activity, sleep, work).

(iv) Opioids and communication. Apologise for dismissive language; reframe as brain–body amplification, not faking. Opioid PRN poly-prescribing is high risk; SPACE shows opioids not superior to non-opioids for function in key chronic pain groups; prefer multimodal non-opioid plan; if OUD criteria emerge, dual-diagnosis pathway with naloxone and addiction care — not abandonment.[5][8]

Common errors

Calling symptoms “not real”; equating SSD with malingering; missing depression/suicide risk; automatic opioid escalation; inventing factitious disorder; and quoting DSM-IV “must be unexplained” logic.[1][5]

Examiner notes

Reward explicit SSD B-criteria, PHQ-15, named CBT trials, duloxetine/TCA practical caution, SPACE, and dual-diagnosis language without stigma.[1][4][5]

References

  1. [1]Dimsdale JE, Creed F, Escobar J, et al. Somatic symptom disorder: an important change in DSM J Psychosom Res, 2013.PMID 23972410
  2. [2]Kroenke K, Spitzer RL, Williams JB The PHQ-15: validity of a new measure for evaluating the severity of somatic symptoms Psychosom Med, 2002.PMID 11914441
  3. [3]Barsky AJ, Ahern DK Cognitive behavior therapy for hypochondriasis: a randomized controlled trial JAMA, 2004.PMID 15039413
  4. [4]Tyrer P, Cooper S, Salkovskis P, et al. Clinical and cost-effectiveness of cognitive behaviour therapy for health anxiety in medical patients: a multicentre randomised controlled trial Lancet, 2014.PMID 24139977
  5. [5]Krebs EE, Gravely A, Nugent S, et al. Effect of Opioid vs Nonopioid Medications on Pain-Related Function in Patients With Chronic Back Pain or Hip or Knee Osteoarthritis Pain: The SPACE Randomized Clinical Trial JAMA, 2018.PMID 29509867
  6. [6]Lunn MP, Hughes RA, Wiffen PJ Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia Cochrane Database Syst Rev, 2014.PMID 24385423
  7. [7]Henningsen P, Zipfel S, Herzog W Management of functional somatic syndromes Lancet, 2007.PMID 17368156
  8. [8]Howe CQ, Sullivan MD The missing 'P' in pain management: how the current opioid epidemic highlights the need for psychiatric services in chronic pain care Gen Hosp Psychiatry, 2014.PMID 24211157